{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:29:23Z","timestamp":1780342163817,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,16]]},"DOI":"10.7759\/cureus.64655","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T15:44:21Z","timestamp":1721144661000},"source":"Crossref","is-referenced-by-count":2,"title":["Lemborexant for the Treatment of Insomnia in Patients From China: Four Case Studies"],"prefix":"10.7759","author":[{"given":"Weiying","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"K\u00e4rpp\u00e4 M","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, et al.. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020, 43:zsaa123. 10.1093\/sleep\/zsaa123","journal-title":"Sleep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a Phase 3 randomized clinical trial","volume":"2","author":"Rosenberg R","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G, et al.. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a Phase 3 randomized clinical trial. JAMA Netw Open. 2019, 2:e1918254. 10.1001\/jamanetworkopen.2019.18254","journal-title":"JAMA Netw Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170772","article-title":"The prevalence of insomnia in the general population in China: a meta-analysis","volume":"12","author":"Cao XL","year":"2017","unstructured":"Cao XL, Wang SB, Zhong BL, et al.. The prevalence of insomnia in the general population in China: a meta-analysis. PLoS One. 2017, 12:e0170772. 10.1371\/journal.pone.0170772","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2022.01.024","article-title":"Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder","volume":"90","author":"Roth T","year":"2022","unstructured":"Roth T, Rosenberg R, Morin CM, et al.. Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Med. 2022, 90:249-57. 10.1016\/j.sleep.2022.01.024","journal-title":"Sleep Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2024.32.e5","article-title":"Emerging and upcoming therapies in insomnia","volume":"32","author":"Kim WJ","year":"2024","unstructured":"Kim WJ, Kim HS. Emerging and upcoming therapies in insomnia. Transl Clin Pharmacol. 2024, 32:1-17. 10.12793\/tcp.2024.32.e5","journal-title":"Transl Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2023.07.023","article-title":"Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study","volume":"110","author":"Yardley J","year":"2023","unstructured":"Yardley J, Inoue Y, Pinner K, Perdomo C, Kubota N, Perlis ML, Moline M. Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study. Sleep Med. 2023, 110:111-9. 10.1016\/j.sleep.2023.07.023","journal-title":"Sleep Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleepx.2022.100044","article-title":"Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder","volume":"4","author":"Dash A","year":"2022","unstructured":"Dash A, Pinner K, Inoue Y, et al.. Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder. Sleep Med X. 2022, 4:100044. 10.1016\/j.sleepx.2022.100044","journal-title":"Sleep Med X"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleepx.2023.100098","article-title":"Transitioning insomnia patients from zolpidem to lemborexant: a multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy","volume":"7","author":"Ahmad M","year":"2024","unstructured":"Ahmad M, Kelly J, Montano CB, et al.. Transitioning insomnia patients from zolpidem to lemborexant: a multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy. Sleep Med X. 2024, 7:100098. 10.1016\/j.sleepx.2023.100098","journal-title":"Sleep Med X"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02811-2","article-title":"Efficacy and safety of transitioning to Lemborexant from Z-drug, suvorexant, and ramelteon in Japanese insomnia patients: an open-label, multicenter study","volume":"41","author":"Ozone M","year":"2024","unstructured":"Ozone M, Hirota S, Ariyoshi Y, et al.. Efficacy and safety of transitioning to Lemborexant from Z-drug, suvorexant, and ramelteon in Japanese insomnia patients: an open-label, multicenter study. Adv Ther. 2024, 41:1728-45. 10.1007\/s12325-024-02811-2","journal-title":"Adv Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2022.2049553","article-title":"Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder","volume":"134","author":"Chepke C","year":"2022","unstructured":"Chepke C, Jain R, Rosenberg R, et al.. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder. Postgrad Med. 2022, 134:316-25. 10.1080\/00325481.2022.2049553","journal-title":"Postgrad Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13470","article-title":"Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: secondary analysis of a randomized clinical trial","volume":"16","author":"Takaesu Y","year":"2023","unstructured":"Takaesu Y, Suzuki M, Moline M, Pinner K, Inabe K, Nishi Y, Kuriyama K. Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: secondary analysis of a randomized clinical trial. Clin Transl Sci. 2023, 16:581-92. 10.1111\/cts.13470","journal-title":"Clin Transl Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001561","article-title":"Abuse potential of Lemborexant, a dual orexin receptor antagonist, compared with zolpidem and suvorexant in recreational sedative users","volume":"42","author":"Landry I","year":"2022","unstructured":"Landry I, Hall N, Aluri J, et al.. Abuse potential of Lemborexant, a dual orexin receptor antagonist, compared with zolpidem and suvorexant in recreational sedative users. J Clin Psychopharmacol. 2022, 42:365-73. 10.1097\/JCP.0000000000001561","journal-title":"J Clin Psychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-040323-031929","article-title":"Orexin receptor antagonism: normalizing sleep architecture in old age and disease","volume":"64","author":"Kron JO","year":"2024","unstructured":"Kron JO, Keenan RJ, Hoyer D, Jacobson LH. Orexin receptor antagonism: normalizing sleep architecture in old age and disease. Annu Rev Pharmacol Toxicol. 2024, 64:359-86. 10.1146\/annurev-pharmtox-040323-031929","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/273421-lemborexant-for-the-treatment-of-insomnia-in-patients-from-china-four-case-studies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T15:44:25Z","timestamp":1721144665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/273421-lemborexant-for-the-treatment-of-insomnia-in-patients-from-china-four-case-studies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.64655","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,16]]}}}